Results 21 to 30 of about 96,641 (177)

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma

Hepatology, 2021
Genetic alterations in intrahepatic cholangiocarcinoma (iCCA) are increasingly well characterized, but their impact on outcome and prognosis remains unknown.
T. Boerner, E. Drill, L. Pak, Bastien Nguyen, C. Sigel, A. Doussot, P. Shin, D. Goldman, M. Gonen, P. Allen, V. Balachandran, A. Cercek, J. Harding, D. Solit, N. Schultz, Ritika Kundra, H. Walch, M. D'Angelica, R. DeMatteo, J. Drebin, N. Kemeny, T. Kingham, Amber L. Simpson, J. Hechtman, E. Vakiani, M. Lowery, J. Ijzermans, S. Buettner, B. Koerkamp, M. Doukas, R. Chandwani, W. Jarnagin   +31 more
semanticscholar   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

Proteogenomic characterization of cholangiocarcinoma

Hepatology, EarlyView., 2022
Proteogenomic characterization of cholangiocarcinoma with therapeutic strategies Abstract Background and Aims Cholangiocarcinoma (CCA) is a highly heterogeneous cancer with limited understanding and few effective therapeutic approaches. We aimed at providing a proteogenomic CCA characterization to inform biological processes and treatment ...
Mengjie Deng, Peng Ran, Lingli Chen, Yunzhi Wang, Zixiang Yu, Ke Cai, Jinwen Feng, Zhaoyu Qin, Yanan Yin, Subei Tan, Yang Liu, Chen Xu, Guoming Shi, Yuan Ji, Jian‐Yuan Zhao, Jian Zhou, Jia Fan, Yingyong Hou, Chen Ding   +18 more
wiley   +1 more source

Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma

American Journal of Transplantation, 2021
Intrahepatic cholangiocarcinoma (iCCA) has previously been considered a contraindication to liver transplantation (LT). However, recent series showed favorable outcomes for LT after neoadjuvant therapy.
Robert McMillan, M. Javle, S. Kodali, A. Saharia, C. Mobley, K. Heyne, M. Hobeika, K. Lunsford, David W. Victor, A. Shetty, Robert S. McFadden, M. Abdelrahim, A. Kaseb, M. Divatia, N. Yu, Joy V. Nolte Fong, Linda W. Moore, D. Nguyen, E. Graviss, A. O. Gaber, J. Vauthey, R. M. Ghobrial   +21 more
semanticscholar   +1 more source

Persistent epigenetic alterations in transcription factors after a sustained virological response in hepatocellular carcinoma

JGH Open, Volume 6, Issue 12, Page 854-863, December 2022., 2022
This study aimed to reveal that abnormalities present in the epigenome play a role in hepatocellular carcinogenesis upon resolution of an hepatitis C virus (HCV) infection. We performed genome‐wide comprehensive epigenome and transcriptome analyses using surgically resected clinical samples and cultured cells.
Keishi Sugimachi, Hiromitsu Araki, Hideyuki Saito, Takaaki Masuda, Fumihito Miura, Kentaro Inoue, Tomonari Shimagaki, Yohei Mano, Tomohiro Iguchi, Masaru Morita, Yasushi Toh, Tomoharu Yoshizumi, Takashi Ito, Koshi Mimori   +13 more
wiley   +1 more source

Cold-atmospheric plasma induces tumor cell death in preclinical in vivo and in vitro models of human cholangiocarcinoma [PDF]

Cancers, 12, 1280, 2020, 2020
Through the last decade, cold atmospheric plasma (CAP) has emerged as an innovative therapeutic option for cancer treatment. Recently, we have set up a potentially safe atmospheric pressure plasma jet device that displays antitumoral properties in a preclinical model of cholangiocarcinoma (CCA), a rare and very aggressive cancer emerging from the ...
arxiv   +1 more source

Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

JAMA Oncology, 2020
Importance Patients with unresectable intrahepatic cholangiocarcinoma (ICC) have a poor prognosis. Selective internal radiotherapy (SIRT) is a promising treatment option for hepatic tumors, but no prospective studies of combination SIRT with chemotherapy
J. Edeline, Y. Touchefeu, B. Guiu, O. Farge, D. Tougeron, I. Baumgaertner, A. Ayav, B. Campillo-Gimenez, L. Beuzit, M. Pracht, A. Lièvre, S. le Sourd, K. Boudjema, Y. Rolland, E. Boucher, E. Garin   +15 more
semanticscholar   +1 more source

Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)

Journal of Hepato-Biliary-Pancreatic Sciences, Volume 30, Issue 1, Page 102-110, January 2023., 2023
Ioka and colleagues present the results of a phase III study comparing gemcitabine and cisplatin plus S‐1 (GCS) with gemcitabine and cisplatin for unresectable or recurrent biliary tract cancer. GCS demonstrated survival benefits and a higher response rate, and could be the new standard chemotherapy for advanced biliary tract cancer.
Tatsuya Ioka, Masashi Kanai, Shogo Kobayashi, Daisuke Sakai, Hidetoshi Eguchi, Hideo Baba, Satoru Seo, Akinobu Taketomi, Tadatoshi Takayama, Hiroki Yamaue, Masahiro Takahashi, Masayuki Sho, Keiko Kamei, Jiro Fujimoto, Masanori Toyoda, Junzo Shimizu, Takuma Goto, Yoshitaro Shindo, Kenichi Yoshimura, Etsuro Hatano, Hiroaki Nagano, Kansai Hepatobiliary Oncology Group (KHBO)   +21 more
wiley   +1 more source

Textbook oncologic outcomes and regionalization among patients undergoing hepatic resection for intrahepatic cholangiocarcinoma

Journal of Surgical Oncology, Volume 127, Issue 1, Page 81-89, January 2023., 2023
Abstract Background and Objectives Textbook oncologic outcome (TOO) and its association with regionalization of care for intrahepatic cholangiocarcinoma (ICC) have not been evaluated. Methods We identified patients who underwent hepatic resection for ICC between 2004 and 2018 from the National Cancer Database.
Muhammad M. Munir, Laura Alaimo, Zorays Moazzam, Yutaka Endo, Henrique A. Lima, Chanza Shaikh, Aslam Ejaz, Joal Beane, Mary Dillhoff, Jordan Cloyd, Timothy M. Pawlik   +10 more
wiley   +1 more source